• The Journal of the Korea institute of electronic communication sciences
• /
• v.11 no.2
• /
• pp.223-228
• /
• 2016

People try to maintain optimal sleep activity to a changing attitude 20-30 times while sleeping 7-8 hours a day. In order to provide optimal sleep, we need to develop sensing device for apply effective various sleep data acquired through display device that can provide program and information which process and analyze information printed out from sensor and sensing system. In this paper, we analyze sleep pattern to detect the toss and turn while a person's sleeping and we develop a wellness pillow that can be active on sleep health management based on the analyzed data for sleep patterns.

• Journal of Families and Better Life
• /
• v.28 no.6
• /
• pp.207-220
• /
• 2010

This study is intended to create a tool which can identify the concept of consumption life level and to develop a standardized scale to measure consumption life level. Based on it, the concept and perspective of consumption life level was formed and then the scale for measuring it was developed. To develop the scale, the scale was firstly formed by extracting questions through a literature survey, and verifying validity through experts' opinions. Then the final scale was developed by conducting a questionnaire survey for consumers. A preliminary 27-item scale was developed through a literature review. 1000 consumers responded to an online survey using the preliminary scale. This research was made with the intention of not only supplying academic data on the consumer's consumption life level but also understanding the consumer's basic behavior patterns. Then a series of tests: test-retest, item-to-total correlation, and Cronbach's reliability coefficient and factor analysis were conducted using the survey data and the final 20-item scale was constructed in the end. The consumer's consumption life level scale consisted of 4 factors.

• Proceedings of the PSK Conference
• /
• 2000.04a
• /
• pp.70-81
• /
• 2000

DA-5018 is a synthetic capsaicin derivative under development as a non-narcotic a analgesic ag$\varepsilon$nt. DA-50 18 showed a potent analgesic activity against acute and chronic pain m model(Tablel, 2.), but it had a narrow margin of safety. DA-5018 did not bind to opioid(${\kappa}, {\delta}, {\mu}$), NKl, CGRP receptors in vitro and its analgesic effect was not antagonized by naloxone, a and it did not develop analgesic tolerance. In addition DA-5018 had no inhibitory effects against c cyclooxygenase and 5-lipooxygenase activities. DA-5018 significantly increased the relcase of substance P from the slices of the rat spinal cord. These results suggest that DA-50 18 is not a narcotic nor aspirin-like analgesic and the release of substance P is one of analgesic mechanism of action of DA-5018. We found that DA-5018 was almost ten times more potent and was at l least IOO-times less irritable compared to capsaicin. Accordingly development of topical formula was adopted. Topical formula was desiged and screened by flux test of DA-5018 using hairless mouse skin and several formulas were selected. With these topical formulas we a assessed the analgesic efficacy and carried out the toxicity, skin irritation and pharmacokinetic studies. In streptozotocin-induced hyperalgesic rat and 50 % galactose-fed hyperalgesic rat as diabetic pain models, DA-5018 cream increased the pain thresh이ds up to 77.0% and 24.4% respectively, while Zostrix-HP(capsaicin cream) incr$\varepsilon$as cd by 65.9% and 21.0%. DA-5018 c cream showed a good analgesic effect as welI in FCA-induced arthritic rat. DA-5018 cream did not show any toxicological signs in acute and chronic toxicity test and had little skin irritation in car swclIing and scratching t$\varepsilon$st. Pharmacokinetics of DA-50 18 were studied after topical application of ${14}^C$-Iabelled or unlabelIed DA-5018 cream. Plasma and skin concentrations c except applied skin wcre below the dctection limit and after 7-day cummulative application, plasma concentrations were also below detection limit DA-50 18 may have an advantag$\varepsilon$ ov$\varepsilon$r c capsaicin and is now being developed as a topical agent for the treatment of pains. DA-50 18 cream was approved for Korean IND and is now under a Phase II clinical study for arthritic pain a after finising Phase I study. DA-50 18 was also liscensed out to Stiefel Company in America in